CXCL12 Signaling in the Tumor Microenvironment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The tumor microenvironment (TME) comprises tumor cells, immune cells, and signaling molecules, influencing cancer progression.
• Chemokines and their receptors, like CXCL12 and its receptors CXCR4/CXCR7, mediate critical cell communication within the TME.
• Dysregulation of the CXCL12 axis is observed in over 20 tumor types, impacting angiogenesis, immune response, and tumor cell behavior.

Purpose of the Study:

• To elucidate the physiological role of CXCL12 and its receptors in cancer biology and the TME.
• To investigate the prognostic significance of the CXCL12 axis in various cancers.
• To review the therapeutic potential of targeting the CXCL12 axis, particularly in overcoming resistance to immune checkpoint inhibitors (ICI).

Main Methods:

• Review of existing literature on CXCL12, CXCR4, CXCR7, and their roles in cancer.
• Analysis of signaling pathways activated by CXCL12-receptor interactions (e.g., CXCR4-mediated pathways).
• Examination of studies linking CXCL12 levels in the TME to ICI resistance and therapeutic strategies.

Main Results:

• The CXCL12/CXCR4/CXCR7 axis is frequently dysregulated in cancer, affecting tumor growth, invasion, and immune evasion.
• High CXCL12 levels in the TME are associated with resistance to ICI therapy.
• Inhibitors of the CXCL12 axis have shown potential in sensitizing resistant tumors to ICI treatment.

Conclusions:

• The CXCL12 axis plays a crucial role in shaping the tumor microenvironment and influencing cancer progression.
• Targeting the CXCL12 axis presents a promising dual therapeutic strategy, impacting both tumor cells and the TME.
• Modulating the CXCL12 axis may enhance the efficacy of immune checkpoint inhibitors in resistant cancers.